Company intelligence / Profile preview

KOMO BIOSCIENCES

Cambridge, Massachusetts, United Stateskomobiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a non-viral, non-nuclease genome engineering platform that has demonstrated large gene insertion (7-15 kb) into a pre-defined, high-expressing region in the human genome at up to 80% integration efficiency per chromosome in up to 96% of cells[2][5].

Modalities: Precision genome engineeringintegrase-mediated cell line development
Industry: Non-Drug Biotech

Partnerships

University of Hawaii (technology licensing)

Beyond the preview

Go deeper on KOMO BIOSCIENCES.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOMO BIOSCIENCES.

Explore the full profile